

**Express Mail Label No. EV 442790040 US  
PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the **PATENT APPLICATION** of:

Smith et al.

**Application No.:** Not Yet Known

**Filed:** Not Yet Known

**For:** RECOMBINANT POXVIRUS

**Group:** Not Yet Known

**Examiner:** Not Yet Known

**Our File:** BWT-PT001.2

**Date:** February 18, 2004

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop **PATENT APPLICATION**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to Applicants' Duty of Disclosure pursuant to 37 C.F.R. §1.56, Applicants wish to bring to the Examiner's attention the material cited on the enclosed PTO-1449 form. Copies of the cited documents are enclosed.

This application is a divisional of U.S. Patent Application No. 10/047,761, filed on January 15, 2002, which is a divisional of U.S. Patent Application No. 09/367,781, filed on November 22, 1999, now U.S. Patent No. 6,355,252, issued on March 12, 2002, which is a Section 371 National Phase of PCT Application No. PCT/GB98/00569, filed February 23, 1998. Pursuant to 37 C.F.R. §1.98(d) copies of documents cited in these


**Applicant:** Smith et al.  
**Application No.:** Not Yet Known

parent applications are not enclosed, but copies will be provided upon request. These documents are identified on the PTO-1449 form by an asterisk (\*).

It is respectfully requested that the Examiner consider these documents and return an initialed copy of the PTO-1449 form indicating his consideration of the cited materials.

Respectfully submitted,

Smith et al.

By   
Ryan W. O'Donnell  
Registration No. 53,401  
(215) 568-6400

Volpe and Koenig, P.C.  
United Plaza, Suite 1600  
30 South 17th Street  
Philadelphia, PA 19103

RWO/djw  
Enclosures

FORM PTO-1449		ATTY. DOCKET NO. BWT-PT001.2		SERIAL NO. Not Yet Known										
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT Smith et al.												
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE Not Yet Known										
(Use several sheets if necessary)		GROUP Not Yet Known												
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
	AA*	6	1	8	4	3	5	8	02/2001	Loetscher et al.				
	AB*	5	8	3	4	4	1	9	11/1998	McFadden et al.				
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION					
	AC*	9	6	3	3	7	3	0	10/1996	PCT			YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
AD*	Virology; Vol 180; Howard et al.; "Vaccinia Virus Homologues of the Shope Fibroma Virus Inverted Terminal Repeat Proteins and a Discontinuous ORF Related to the Tumor Necrosis Factor Receptor Family"; January 1991; pp. 633-647.													
AE*	Current Opinion In Immunology; Vol. 8; No. 4; Geoffrey L. Smith; "Virus Proteins That Bind Cytokines, Chemokines or Interferons"; August 1996; pp. 467-471.													
AF*	Journal Of Experimental Medicine; Vol. 184; No. 3; Loetscher et al.; "Chemokine receptor specific for IP10. and MIG: Structure, Function, and Expression in Activated T-lymphocytes"; September 1996; pp. 963-969													
AG*	Ng, Aylwin, Ph.D. Thesis, University of Oxford (1998). The Vaccinia Virus A41L Gene Encodes a Novel Secreted Immunomodulatory Factor.													
AH*	Ng, A. Tschärke, D.C., Reading, P.D. & Smith, G.L. (2001). The vaccinia virus A41L protein is a soluble 30kDa protein that affects virus virulence. Journal of General Virology 82 2095-2105													
AI*	Nikolaevich et al. Two types of detections in Orthopoxvirus genomes. Virus Genese. Vol. 9, No. 3 (1995) pp. 231-245													
AJ*	Jackson et al. Expression of mouse interleukin-4 by a recombinant ectomelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. Journal of Virology. Vol 75, No. 3 (2001) pp. 1205-1210													
EXAMINER						DATE CONSIDERED								

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.